首页 > 最新文献

Pain Practice最新文献

英文 中文
Semi‐invasive therapies for pain in knee osteoarthritis: A systematic review and network meta‐analysis
IF 2.6 3区 医学 Q2 ANESTHESIOLOGY Pub Date : 2024-09-13 DOI: 10.1111/papr.13404
Siew‐Li Goh, Melissa Wee Chong, Jerri Ling, Zulkarnain Jaafar, Zhuang‐Li Lim, May‐Yann Yau, Terence Ong, Jim Richards
BackgroundThe increasing number of semi‐invasive pain therapies in knee osteoarthritis poses challenges in decision‐making. This review aimed to simultaneously compare established intra‐articular therapies with newer peri‐articular therapies and explore effect modifiers.MethodsRandomized controlled trials were searched from five electronic databases without date or language restrictions. Study selection and data extraction of reports, retrieved up to May 2024, were performed independently by paired assessors. The primary outcome was 6‐month pain score. Nine treatments were included. The effect size (ES) for each treatment, relative to placebo, was estimated using standardized means difference and expressed with 95% confidence intervals (CI). The rigor of results was evaluated with subgroup/sensitivity analyses.ResultsA total of 111 studies (14,695 participants) were included, with intra‐articular hyaluronic acid having the greatest number of participants. Neuroablation demonstrated the greatest ES (1.08, 95% CI: 0.07, 2.10). While platelet‐rich plasma (PRP) ranked second (ES: 0.75, 95% CI: 0.28, 1.22), it was the only intervention demonstrating statistically significant effect at 3, 6, and 12 months. However, this statistical significance was lost in some sensitivity analyses. Larger estimates for biologics and PRP compared with prolotherapy, steroid, and hyaluronic acid injections were consistently observed across different timepoints and in multiple sensitivity analyses. Generally, no statistically significant difference was found between the nine types of therapies.ConclusionAlthough there is robust evidence suggesting greater efficacy of PRP, potentially including biologics, over other interventions, future research is needed to identify the phenotype or patient subgroup that would benefit most from PRP.
背景膝关节骨关节炎的半侵入性疼痛疗法越来越多,给决策带来了挑战。本综述旨在同时比较既有的关节内疗法和较新的关节周围疗法,并探讨效果调节因素。方法在五个电子数据库中检索随机对照试验,无日期或语言限制。截至 2024 年 5 月检索到的研究选择和报告数据提取均由配对评估员独立完成。主要结果为 6 个月的疼痛评分。共纳入九种治疗方法。每种疗法相对于安慰剂的效应大小 (ES) 采用标准化均值差估算,并用 95% 置信区间 (CI) 表示。结果 共纳入了 111 项研究(14,695 人参与),其中关节内透明质酸的参与人数最多。神经消融的ES值最大(1.08,95% CI:0.07,2.10)。富血小板血浆 (PRP) 排名第二(ES:0.75,95% CI:0.28,1.22),是唯一一种在 3、6 和 12 个月时具有显著统计学效果的干预方法。然而,在一些敏感性分析中,这种统计学意义消失了。在不同的时间点和多个敏感性分析中,均持续观察到生物制剂和 PRP 与增殖疗法、类固醇和透明质酸注射相比,具有更大的估计值。结论虽然有确凿证据表明 PRP(可能包括生物制剂)比其他干预措施具有更高的疗效,但未来仍需开展研究,以确定从 PRP 中获益最多的表型或患者亚群。
{"title":"Semi‐invasive therapies for pain in knee osteoarthritis: A systematic review and network meta‐analysis","authors":"Siew‐Li Goh, Melissa Wee Chong, Jerri Ling, Zulkarnain Jaafar, Zhuang‐Li Lim, May‐Yann Yau, Terence Ong, Jim Richards","doi":"10.1111/papr.13404","DOIUrl":"https://doi.org/10.1111/papr.13404","url":null,"abstract":"BackgroundThe increasing number of semi‐invasive pain therapies in knee osteoarthritis poses challenges in decision‐making. This review aimed to simultaneously compare established intra‐articular therapies with newer peri‐articular therapies and explore effect modifiers.MethodsRandomized controlled trials were searched from five electronic databases without date or language restrictions. Study selection and data extraction of reports, retrieved up to May 2024, were performed independently by paired assessors. The primary outcome was 6‐month pain score. Nine treatments were included. The effect size (ES) for each treatment, relative to placebo, was estimated using standardized means difference and expressed with 95% confidence intervals (CI). The rigor of results was evaluated with subgroup/sensitivity analyses.ResultsA total of 111 studies (14,695 participants) were included, with intra‐articular hyaluronic acid having the greatest number of participants. Neuroablation demonstrated the greatest ES (1.08, 95% CI: 0.07, 2.10). While platelet‐rich plasma (PRP) ranked second (ES: 0.75, 95% CI: 0.28, 1.22), it was the only intervention demonstrating statistically significant effect at 3, 6, and 12 months. However, this statistical significance was lost in some sensitivity analyses. Larger estimates for biologics and PRP compared with prolotherapy, steroid, and hyaluronic acid injections were consistently observed across different timepoints and in multiple sensitivity analyses. Generally, no statistically significant difference was found between the nine types of therapies.ConclusionAlthough there is robust evidence suggesting greater efficacy of PRP, potentially including biologics, over other interventions, future research is needed to identify the phenotype or patient subgroup that would benefit most from PRP.","PeriodicalId":19974,"journal":{"name":"Pain Practice","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142268624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Elevated lead impedances in spinal cord stimulation systems 脊髓刺激系统的导联阻抗升高
IF 2.6 3区 医学 Q2 ANESTHESIOLOGY Pub Date : 2024-09-13 DOI: 10.1111/papr.13415
Alaa Abd‐Elsayed, Christopher Gilligan
{"title":"Elevated lead impedances in spinal cord stimulation systems","authors":"Alaa Abd‐Elsayed, Christopher Gilligan","doi":"10.1111/papr.13415","DOIUrl":"https://doi.org/10.1111/papr.13415","url":null,"abstract":"","PeriodicalId":19974,"journal":{"name":"Pain Practice","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142268625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low‐energy differential target multiplexed SCS derivative reduces pain and improves quality of life through 12 months in patients with chronic back and/or leg pain 低能量差分靶向多路复用体外脊髓刺激疗法衍生物可在 12 个月内减轻慢性背痛和/或腿痛患者的疼痛并改善其生活质量
IF 2.6 3区 医学 Q2 ANESTHESIOLOGY Pub Date : 2024-09-11 DOI: 10.1111/papr.13407
Jeffery Peacock, David Provenzano, Michael Fishman, Kasra Amirdelfan, Todd Bromberg, Todd Schmidt, Thomas White, Prabhdeep Grewal, Rafael Justiz, Aaron Calodney, Amr El‐Naggar, Binit Shah, Michael Esposito, Kliment Gatzinsky, Jan Willem Kallewaard, Lawrence Poree, Andrew Cleland, Calysta Rice, Erin Theis, Kate Noel, Maddie LaRue
IntroductionEnergy‐reducing spinal cord stimulation (SCS) approaches have the potential to impact patient experience with rechargeable and non‐rechargeable SCS devices through reducing device recharge time or enhancing device longevity. This prospective, multi‐center study evaluated the safety, effectiveness, and actual energy usage of differential target multiplexed (DTM) endurance therapy, a reduced energy DTM SCS derivative.MethodsSubjects who reported an overall pain visual analog score (VAS) of ≥6/10 cm and an Oswestry Disability Index score of 21–80 out of 100 at baseline with moderate to severe chronic, intractable back and/or leg pain were eligible. Evaluation visits occurred at 1, 3, 6, and 12 months post‐device activation. The primary objective was to characterize change in overall pain intensity, as measured by VAS, from baseline to 3‐month visit.ResultsFifty‐seven subjects enrolled at 12 US sites from November 2020 through June 2021, 35 were implanted with a rechargeable SCS device, and 27 completed the 12‐month visit. Subjects experienced a 50.4% mean reduction in overall pain from baseline at the 3‐month follow‐up that was sustained through 12 months. Additional outcomes including changes in overall, back, and leg pain intensity, quality of life, disability, therapy satisfaction, safety, and current battery usage are shown through 12‐month follow‐up.ConclusionThe use of DTM endurance SCS therapy in this study resulted in reductions in pain relief through 12 months, demonstrating that energy‐reducing stimulation patterns can provide clinical benefit. Clinically effective, reduced energy SCS derivatives have the potential to impact patient experience through either reduced recharge requirements or increased device longevity.
导言减少能量的脊髓刺激(SCS)方法有可能通过减少设备充电时间或延长设备寿命来影响患者使用可充电和不可充电 SCS 设备的体验。这项前瞻性多中心研究评估了差分靶向多路复用(DTM)耐力疗法(一种降低能量的 DTM SCS 衍生物)的安全性、有效性和实际能量使用情况。方法基线时报告总体疼痛视觉模拟评分(VAS)≥6/10 厘米、Oswestry 残疾指数评分(满分 100 分,21-80 分)为中度至重度慢性顽固性背部和/或腿部疼痛的受试者均符合条件。评估访问在设备激活后的 1、3、6 和 12 个月进行。结果2020 年 11 月至 2021 年 6 月期间,57 名受试者在美国的 12 个地点注册,35 名受试者植入了可充电 SCS 装置,27 名受试者完成了 12 个月的访问。在 3 个月的随访中,受试者的总体疼痛平均比基线减轻了 50.4%,并持续了 12 个月。其他结果包括总体、背部和腿部疼痛强度、生活质量、残疾程度、治疗满意度、安全性和当前电池使用情况的变化,这些结果都显示在 12 个月的随访中。临床有效的减能量 SCS 衍生物有可能通过降低充电要求或延长设备寿命来影响患者的体验。
{"title":"Low‐energy differential target multiplexed SCS derivative reduces pain and improves quality of life through 12 months in patients with chronic back and/or leg pain","authors":"Jeffery Peacock, David Provenzano, Michael Fishman, Kasra Amirdelfan, Todd Bromberg, Todd Schmidt, Thomas White, Prabhdeep Grewal, Rafael Justiz, Aaron Calodney, Amr El‐Naggar, Binit Shah, Michael Esposito, Kliment Gatzinsky, Jan Willem Kallewaard, Lawrence Poree, Andrew Cleland, Calysta Rice, Erin Theis, Kate Noel, Maddie LaRue","doi":"10.1111/papr.13407","DOIUrl":"https://doi.org/10.1111/papr.13407","url":null,"abstract":"IntroductionEnergy‐reducing spinal cord stimulation (SCS) approaches have the potential to impact patient experience with rechargeable and non‐rechargeable SCS devices through reducing device recharge time or enhancing device longevity. This prospective, multi‐center study evaluated the safety, effectiveness, and actual energy usage of differential target multiplexed (DTM) endurance therapy, a reduced energy DTM SCS derivative.MethodsSubjects who reported an overall pain visual analog score (VAS) of ≥6/10 cm and an Oswestry Disability Index score of 21–80 out of 100 at baseline with moderate to severe chronic, intractable back and/or leg pain were eligible. Evaluation visits occurred at 1, 3, 6, and 12 months post‐device activation. The primary objective was to characterize change in overall pain intensity, as measured by VAS, from baseline to 3‐month visit.ResultsFifty‐seven subjects enrolled at 12 US sites from November 2020 through June 2021, 35 were implanted with a rechargeable SCS device, and 27 completed the 12‐month visit. Subjects experienced a 50.4% mean reduction in overall pain from baseline at the 3‐month follow‐up that was sustained through 12 months. Additional outcomes including changes in overall, back, and leg pain intensity, quality of life, disability, therapy satisfaction, safety, and current battery usage are shown through 12‐month follow‐up.ConclusionThe use of DTM endurance SCS therapy in this study resulted in reductions in pain relief through 12 months, demonstrating that energy‐reducing stimulation patterns can provide clinical benefit. Clinically effective, reduced energy SCS derivatives have the potential to impact patient experience through either reduced recharge requirements or increased device longevity.","PeriodicalId":19974,"journal":{"name":"Pain Practice","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142185066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
10. Complex regional pain syndrome 10.复杂区域疼痛综合征
IF 2.6 3区 医学 Q2 ANESTHESIOLOGY Pub Date : 2024-09-11 DOI: 10.1111/papr.13413
Daniël P. C. van der Spek, Maaike Dirckx, Thomas J. P. Mangnus, Steven P. Cohen, Frank J. P. M. Huygen
IntroductionComplex regional pain syndrome (CRPS) is a clinical disorder that can develop following surgery or trauma. Based on the most prominent underlying pathophysiological mechanisms, CRPS can be classified into different subtypes, namely inflammatory, nociplastic/neuropathic, vasomotor, and motor. Depending on the subtype, personalized treatment can be applied. If conservative treatments are insufficient or ineffective, more invasive treatments may be recommended. This article provides an overview of the most recent insights into CRPS and discusses the most common invasive treatments.MethodsThe literature regarding interventional treatments for CRPS has been systematically reviewed and summarized.ResultsBisphosphonates are effective in treating the inflammatory subtype, while ketamine can provide pain relief for the nociplastic/neuropathic subtype. Sympathetic blocks are effective in addressing vasomotor disturbances. For patients with refractory symptoms, neurostimulation is a viable option due to its multimechanistic properties for all subtypes. End‐of‐line motor disturbances may benefit from intrathecal baclofen.ConclusionsCRPS is a debilitating condition with an unpredictable course. The effectiveness of treatment varies from patient to patient. When conservative approaches prove insufficient, gradual progression to invasive treatments based on the underlying subtype is recommended.
导言 复杂区域性疼痛综合征(CRPS)是一种临床疾病,可在手术或创伤后发生。根据最突出的潜在病理生理机制,CRPS 可分为不同的亚型,即炎症型、神经痉挛/神经病理性型、血管运动型和运动型。根据亚型的不同,可以采用个性化的治疗方法。如果保守治疗不足或无效,可能会建议采用更具侵入性的治疗方法。本文概述了对CRPS的最新见解,并讨论了最常见的侵入性治疗方法。结果双膦酸盐可有效治疗炎症亚型,而氯胺酮可缓解非痉挛性/神经病理性亚型的疼痛。交感神经阻滞可有效解决血管运动障碍。对于有难治性症状的患者,神经刺激是一种可行的选择,因为它具有针对所有亚型的多机制特性。结论 CRPS 是一种使人衰弱的疾病,病程难以预测。治疗效果因人而异。当保守治疗效果不佳时,建议根据潜在的亚型逐步过渡到侵入性治疗。
{"title":"10. Complex regional pain syndrome","authors":"Daniël P. C. van der Spek, Maaike Dirckx, Thomas J. P. Mangnus, Steven P. Cohen, Frank J. P. M. Huygen","doi":"10.1111/papr.13413","DOIUrl":"https://doi.org/10.1111/papr.13413","url":null,"abstract":"IntroductionComplex regional pain syndrome (CRPS) is a clinical disorder that can develop following surgery or trauma. Based on the most prominent underlying pathophysiological mechanisms, CRPS can be classified into different subtypes, namely inflammatory, nociplastic/neuropathic, vasomotor, and motor. Depending on the subtype, personalized treatment can be applied. If conservative treatments are insufficient or ineffective, more invasive treatments may be recommended. This article provides an overview of the most recent insights into CRPS and discusses the most common invasive treatments.MethodsThe literature regarding interventional treatments for CRPS has been systematically reviewed and summarized.ResultsBisphosphonates are effective in treating the inflammatory subtype, while ketamine can provide pain relief for the nociplastic/neuropathic subtype. Sympathetic blocks are effective in addressing vasomotor disturbances. For patients with refractory symptoms, neurostimulation is a viable option due to its multimechanistic properties for all subtypes. End‐of‐line motor disturbances may benefit from intrathecal baclofen.ConclusionsCRPS is a debilitating condition with an unpredictable course. The effectiveness of treatment varies from patient to patient. When conservative approaches prove insufficient, gradual progression to invasive treatments based on the underlying subtype is recommended.","PeriodicalId":19974,"journal":{"name":"Pain Practice","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142185065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Smaller thoracic canal diameters are associated with thoracic radiculopathy and abdominal pain after spinal cord stimulator paddle lead placement. 较小的胸椎管直径与脊髓刺激器桨状导联线置入后的胸椎根性病变和腹痛有关。
IF 2.5 3区 医学 Q2 ANESTHESIOLOGY Pub Date : 2024-09-06 DOI: 10.1111/papr.13414
Brian T Ragel, Matthew McGehee, Nicolas Karvelas, Ahmed M Raslan

Introduction: It is not uncommon for patients to experience postoperative neurologic deficit, thoracic radiculopathy, abdominal pain, or lower extremity paresthesia after the implantation of thoracic spinal cord stimulator (SCS) paddle leads. Smaller thoracic canal diameters have previously been associated with postoperative neurologic deficits.

Objective: This imaging study examined whether postoperative SCS neurologic complaints other than neurologic deficit may be correlated with thoracic spinal canal diameter.

Methods: Patients who underwent thoracic laminotomy for SCS paddle lead placement between January 2018 and March 2023 were identified. Preoperative thoracic canal diameter was measured on MRI or CT imaging in the sagittal plane from T5/6 to T11/12. The canal diameters of patients with and without new postoperative neurologic complaints were compared.

Results: Two hundred forty-six patients underwent thoracic laminotomy for SCS paddle lead placement. Thoracic radiculopathy, abdominal pain, and lower extremity paresthesia occurred in 3.7% (9/246), 2.8% (7/246), and 2.0% (5/246) patients, respectively. The mean canal diameter for patients without neurologic complaint, thoracic radiculopathy, abdominal pain, and lower extremity paresthesia was 13.1 mm, 12.0 mm (p < 0.0001), 12.1 mm (p < 0.01), and 12.8 mm (p = 0.365), respectively.

Conclusion: A smaller thoracic canal diameter is associated with postoperative thoracic radiculopathy and abdominal pain. We believe that surgical planning to create adequate space for SCS leads is critical in preventing postoperative neurologic complaints of deficit, thoracic radiculopathy, and abdominal pain.

导言:植入胸椎脊髓刺激器(SCS)桨状导线后,患者术后出现神经功能缺损、胸椎根性病变、腹痛或下肢麻痹的情况并不少见。较小的胸椎管直径曾与术后神经功能缺损有关:本影像学研究探讨了 SCS 术后除神经功能缺损外的其他神经症状是否与胸椎管直径相关:确定了 2018 年 1 月至 2023 年 3 月间因 SCS 桨状导联置入而接受胸椎椎板切开术的患者。术前胸椎管直径通过 MRI 或 CT 成像在 T5/6 至 T11/12 的矢状面上进行测量。对术后出现和未出现新的神经系统症状的患者的胸椎管直径进行比较:结果:246 名患者接受了胸椎椎板切除术,以植入 SCS 桨状导联。分别有 3.7%(9/246)、2.8%(7/246)和 2.0%(5/246)的患者出现胸椎根性病变、腹痛和下肢麻痹。无神经系统主诉、胸椎根性病变、腹痛和下肢麻痹的患者的胸椎管平均直径分别为 13.1 毫米、12.0 毫米(p 结论:胸椎管直径越小,下肢麻痹越严重:较小的胸椎管直径与术后胸椎根性病变和腹痛有关。我们认为,为 SCS 导联创造足够空间的手术规划对于预防术后神经功能缺损、胸椎根性病变和腹痛等症状至关重要。
{"title":"Smaller thoracic canal diameters are associated with thoracic radiculopathy and abdominal pain after spinal cord stimulator paddle lead placement.","authors":"Brian T Ragel, Matthew McGehee, Nicolas Karvelas, Ahmed M Raslan","doi":"10.1111/papr.13414","DOIUrl":"https://doi.org/10.1111/papr.13414","url":null,"abstract":"<p><strong>Introduction: </strong>It is not uncommon for patients to experience postoperative neurologic deficit, thoracic radiculopathy, abdominal pain, or lower extremity paresthesia after the implantation of thoracic spinal cord stimulator (SCS) paddle leads. Smaller thoracic canal diameters have previously been associated with postoperative neurologic deficits.</p><p><strong>Objective: </strong>This imaging study examined whether postoperative SCS neurologic complaints other than neurologic deficit may be correlated with thoracic spinal canal diameter.</p><p><strong>Methods: </strong>Patients who underwent thoracic laminotomy for SCS paddle lead placement between January 2018 and March 2023 were identified. Preoperative thoracic canal diameter was measured on MRI or CT imaging in the sagittal plane from T5/6 to T11/12. The canal diameters of patients with and without new postoperative neurologic complaints were compared.</p><p><strong>Results: </strong>Two hundred forty-six patients underwent thoracic laminotomy for SCS paddle lead placement. Thoracic radiculopathy, abdominal pain, and lower extremity paresthesia occurred in 3.7% (9/246), 2.8% (7/246), and 2.0% (5/246) patients, respectively. The mean canal diameter for patients without neurologic complaint, thoracic radiculopathy, abdominal pain, and lower extremity paresthesia was 13.1 mm, 12.0 mm (p < 0.0001), 12.1 mm (p < 0.01), and 12.8 mm (p = 0.365), respectively.</p><p><strong>Conclusion: </strong>A smaller thoracic canal diameter is associated with postoperative thoracic radiculopathy and abdominal pain. We believe that surgical planning to create adequate space for SCS leads is critical in preventing postoperative neurologic complaints of deficit, thoracic radiculopathy, and abdominal pain.</p>","PeriodicalId":19974,"journal":{"name":"Pain Practice","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142140776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
11. Cervicogenic headache and occipital neuralgia. 11.颈源性头痛和枕神经痛。
IF 2.5 3区 医学 Q2 ANESTHESIOLOGY Pub Date : 2024-09-01 DOI: 10.1111/papr.13405
Nicole Lefel, Hans van Suijlekom, Steven P C Cohen, Jan Willem Kallewaard, Jan Van Zundert

Introduction: Cervicogenic headache (CEH) and occipital neuralgia (ON) are headaches originating in the occiput and that radiate to the vertex. Because of the intimate relationship between structures based in the occiput and those in the upper cervical region, there is significant overlap between the presentation of CEH and ON. Diagnosis starts with a headache history to assess for diagnostic criteria formulated by the International Headache Society. Physical examination evaluates range of motion of the neck and the presence of tender areas or pressure points.

Methods: The literature for the diagnosis and treatment of CEH and ON was searched from 2015 through August 2022, retrieved, and summarized.

Results: Conservative treatment includes pain education and self-care, analgesic medication, physical therapy (such as reducing secondary muscle tension and improving posture), the use of TENS (transcutaneous electrical nerve stimulation), or a combination of the aforementioned treatments. Injection at various anatomical locations with local anesthetic with or without corticosteroids can provide pain relief for a short period. Deep cervical plexus block can result in improved pain for less than 6 months. In both CEH and ON, an occipital nerve block can provide important diagnostic information and improve pain in some patients, with PRF providing greater long-term pain control. Radiofrequency ablation of the cervical facet joints can result in improvement for over 1 year. Occipital nerve stimulation (ONS) should be considered for the treatment of refractory ON.

Conclusion: The treatment of CEH preferentially consists of radiofrequency treatment of the facet joints, while for ON, pulsed radiofrequency of the occipital nerves is indicated. For refractory cases, ONS may be considered.

导言:颈源性头痛(CEH)和枕神经痛(ON)是源于枕部并放射至顶点的头痛。由于枕部结构与上颈部结构之间的密切关系,颈源性头痛和枕神经痛的表现形式有很大的重叠。诊断首先要了解头痛病史,评估是否符合国际头痛协会制定的诊断标准。体格检查主要评估颈部的活动范围以及是否存在压痛区或压痛点:方法:检索了2015年至2022年8月有关CEH和ON诊断和治疗的文献,并进行了检索和总结:保守治疗包括疼痛教育和自我护理、镇痛药物、物理治疗(如减轻继发性肌肉紧张和改善姿势)、使用TENS(经皮神经电刺激)或上述治疗方法的组合。在不同的解剖位置注射局部麻醉剂,同时使用或不使用皮质类固醇,可在短期内缓解疼痛。深部颈丛神经阻滞可使疼痛在 6 个月内得到改善。在 CEH 和 ON 中,枕神经阻滞可提供重要的诊断信息,并改善部分患者的疼痛,而 PRF 可提供更好的长期疼痛控制。颈椎面关节射频消融术可使疼痛改善超过 1 年。在治疗难治性颈椎病时,应考虑使用枕神经刺激疗法(ONS):结论:治疗颈椎病的首选方法是对关节面进行射频治疗,而治疗颈椎病的方法则是对枕神经进行脉冲射频治疗。对于难治性病例,可考虑使用 ONS。
{"title":"11. Cervicogenic headache and occipital neuralgia.","authors":"Nicole Lefel, Hans van Suijlekom, Steven P C Cohen, Jan Willem Kallewaard, Jan Van Zundert","doi":"10.1111/papr.13405","DOIUrl":"https://doi.org/10.1111/papr.13405","url":null,"abstract":"<p><strong>Introduction: </strong>Cervicogenic headache (CEH) and occipital neuralgia (ON) are headaches originating in the occiput and that radiate to the vertex. Because of the intimate relationship between structures based in the occiput and those in the upper cervical region, there is significant overlap between the presentation of CEH and ON. Diagnosis starts with a headache history to assess for diagnostic criteria formulated by the International Headache Society. Physical examination evaluates range of motion of the neck and the presence of tender areas or pressure points.</p><p><strong>Methods: </strong>The literature for the diagnosis and treatment of CEH and ON was searched from 2015 through August 2022, retrieved, and summarized.</p><p><strong>Results: </strong>Conservative treatment includes pain education and self-care, analgesic medication, physical therapy (such as reducing secondary muscle tension and improving posture), the use of TENS (transcutaneous electrical nerve stimulation), or a combination of the aforementioned treatments. Injection at various anatomical locations with local anesthetic with or without corticosteroids can provide pain relief for a short period. Deep cervical plexus block can result in improved pain for less than 6 months. In both CEH and ON, an occipital nerve block can provide important diagnostic information and improve pain in some patients, with PRF providing greater long-term pain control. Radiofrequency ablation of the cervical facet joints can result in improvement for over 1 year. Occipital nerve stimulation (ONS) should be considered for the treatment of refractory ON.</p><p><strong>Conclusion: </strong>The treatment of CEH preferentially consists of radiofrequency treatment of the facet joints, while for ON, pulsed radiofrequency of the occipital nerves is indicated. For refractory cases, ONS may be considered.</p>","PeriodicalId":19974,"journal":{"name":"Pain Practice","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142110804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Triptan treatment is associated with a higher number of red wine-induced migraine episodes: An exploratory questionnaire-based survey. 服用阿普唑仑与红葡萄酒诱发偏头痛发作次数增加有关:一项基于问卷的探索性调查。
IF 2.5 3区 医学 Q2 ANESTHESIOLOGY Pub Date : 2024-09-01 DOI: 10.1111/papr.13412
Saad Masood, Muhammad Ahrar Bin Naeem, Muhammad Qasim, Javeeria Arshad
{"title":"Triptan treatment is associated with a higher number of red wine-induced migraine episodes: An exploratory questionnaire-based survey.","authors":"Saad Masood, Muhammad Ahrar Bin Naeem, Muhammad Qasim, Javeeria Arshad","doi":"10.1111/papr.13412","DOIUrl":"https://doi.org/10.1111/papr.13412","url":null,"abstract":"","PeriodicalId":19974,"journal":{"name":"Pain Practice","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142110806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
9. Chronic knee pain. 9.慢性膝关节疼痛
IF 2.5 3区 医学 Q2 ANESTHESIOLOGY Pub Date : 2024-09-01 DOI: 10.1111/papr.13408
Thibaut Vanneste, Amy Belba, Gezina T M L Oei, Pieter Emans, Loic Fonkoue, Jan Willem Kallewaard, Leonardo Kapural, Philip Peng, Michael Sommer, Bert Vanneste, Steven P Cohen, Jan Van Zundert

Introduction: Chronic knee pain is defined as pain that persists or recurs over 3 months. The most common is degenerative osteoarthritis (OA). This review represents a comprehensive description of the pathology, diagnosis, and treatment of OA of the knee.

Methods: The literature on the diagnosis and treatment of chronic knee pain was retrieved and summarized. A modified Delphi approach was used to formulate recommendations on interventional treatments.

Results: Patients with knee OA commonly present with insidious, chronic knee pain that gradually worsens. Pain caused by knee OA is predominantly nociceptive pain, with occasional nociplastic and infrequent neuropathic characteristics occurring in a diseased knee. A standard musculoskeletal and neurological examination is required for the diagnosis of knee OA. Although typical clinical OA findings are sufficient for diagnosis, medical imaging may be performed to improve specificity. The differential diagnosis should exclude other causes of knee pain including bone and joint disorders such as rheumatoid arthritis, spondylo- and other arthropathies, and infections. When conservative treatment fails, intra-articular injections of corticosteroids and radiofrequency (conventional and cooled) of the genicular nerves have been shown to be effective. Hyaluronic acid infiltrations are conditionally recommended. Platelet-rich plasma infiltrations, chemical ablation of genicular nerves, and neurostimulation have, at the moment, not enough evidence and can be considered in a study setting. The decision to perform joint-preserving and joint-replacement options should be made multidisciplinary.

Conclusions: When conservative measures fail to provide satisfactory pain relief, a multidisciplinary approach is recommended including psychological therapy, integrative treatments, and procedural options such as intra-articular injections, radiofrequency ablation, and surgery.

简介慢性膝关节疼痛是指持续或复发超过 3 个月的疼痛。最常见的是退行性骨关节炎(OA)。本综述全面描述了膝关节 OA 的病理、诊断和治疗:方法:检索并总结了有关慢性膝关节疼痛诊断和治疗的文献。结果:膝关节OA患者通常表现为膝关节内侧疼痛:结果:膝关节 OA 患者通常表现为隐匿性慢性膝关节疼痛,并逐渐加重。膝关节 OA 引起的疼痛主要是痛觉性疼痛,病变膝关节偶尔会出现神经痉挛性疼痛,神经病理性疼痛并不常见。诊断膝关节 OA 需要进行标准的肌肉骨骼和神经系统检查。虽然典型的临床 OA 检查结果足以确诊,但仍可进行医学影像检查以提高特异性。鉴别诊断应排除引起膝关节疼痛的其他原因,包括类风湿性关节炎、脊柱关节病和其他关节病等骨关节疾病以及感染。当保守治疗无效时,关节内注射皮质类固醇和对膝关节神经进行射频(传统和冷却)治疗已被证明有效。有条件地推荐使用透明质酸浸润疗法。富血小板血浆浸润、膝关节神经化学消融和神经刺激目前还没有足够的证据,可在研究环境中考虑。结论:当保守疗法无法提供满意的止痛效果时,可以考虑使用关节置换术:结论:当保守治疗无法提供满意的疼痛缓解效果时,建议采用多学科方法,包括心理治疗、综合治疗以及关节内注射、射频消融和手术等程序性选择。
{"title":"9. Chronic knee pain.","authors":"Thibaut Vanneste, Amy Belba, Gezina T M L Oei, Pieter Emans, Loic Fonkoue, Jan Willem Kallewaard, Leonardo Kapural, Philip Peng, Michael Sommer, Bert Vanneste, Steven P Cohen, Jan Van Zundert","doi":"10.1111/papr.13408","DOIUrl":"https://doi.org/10.1111/papr.13408","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic knee pain is defined as pain that persists or recurs over 3 months. The most common is degenerative osteoarthritis (OA). This review represents a comprehensive description of the pathology, diagnosis, and treatment of OA of the knee.</p><p><strong>Methods: </strong>The literature on the diagnosis and treatment of chronic knee pain was retrieved and summarized. A modified Delphi approach was used to formulate recommendations on interventional treatments.</p><p><strong>Results: </strong>Patients with knee OA commonly present with insidious, chronic knee pain that gradually worsens. Pain caused by knee OA is predominantly nociceptive pain, with occasional nociplastic and infrequent neuropathic characteristics occurring in a diseased knee. A standard musculoskeletal and neurological examination is required for the diagnosis of knee OA. Although typical clinical OA findings are sufficient for diagnosis, medical imaging may be performed to improve specificity. The differential diagnosis should exclude other causes of knee pain including bone and joint disorders such as rheumatoid arthritis, spondylo- and other arthropathies, and infections. When conservative treatment fails, intra-articular injections of corticosteroids and radiofrequency (conventional and cooled) of the genicular nerves have been shown to be effective. Hyaluronic acid infiltrations are conditionally recommended. Platelet-rich plasma infiltrations, chemical ablation of genicular nerves, and neurostimulation have, at the moment, not enough evidence and can be considered in a study setting. The decision to perform joint-preserving and joint-replacement options should be made multidisciplinary.</p><p><strong>Conclusions: </strong>When conservative measures fail to provide satisfactory pain relief, a multidisciplinary approach is recommended including psychological therapy, integrative treatments, and procedural options such as intra-articular injections, radiofrequency ablation, and surgery.</p>","PeriodicalId":19974,"journal":{"name":"Pain Practice","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142110805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Determinants of successful opioid deprescribing: Insights from French pain physicians-A qualitative study. 成功取消阿片类药物处方的决定因素:法国疼痛科医生的见解--一项定性研究。
IF 2.5 3区 医学 Q2 ANESTHESIOLOGY Pub Date : 2024-08-28 DOI: 10.1111/papr.13409
Pierre Nizet, Laure Deme, Adrien Evin, Emmanuelle Kuhn, Julien Nizard, Caroline Victorri Vigneau, Jean-François Huon

Background: Long-term use of opioids does not result in significant clinical improvement and has shown more adverse than beneficial effects in chronic pain conditions. When opioids cause more adverse effects than benefits for the patient, it may be necessary to initiate a process of deprescribing.

Aim: To explore the perceptions of French pain physicians regarding the process of opioid deprescribing in patients experiencing chronic non-cancer and to generate an understanding of the barriers and levers to the deprescribing process.

Methods: We conducted a multicentric observational study with qualitative approach. Individual semi-structured interviews exploring pain physicians' perceptions, beliefs, and representations to assess the determinants of opioid deprescribing with an interview guide were used. After checking the transcripts, an inductive and independent thematic analysis of the interviews was to extract meaningful themes from the dataset.

Results: Twelve pain physicians were interviewed. The main obstacles to deprescribing revolved around patient-specific attributes, characteristics of the opioids themselves, and limitations within the current healthcare system, that hinder optimal patient management. Conversely, patient motivation and education, recourse to hospitalization in a Pain Department with multidisciplinary care, follow-up by the general practitioner, and training and information dissemination among patients and clinicians emerged as facilitative elements for opioid deprescribing.

Conclusion: This study underscores the needs to improve the training of healthcare professionals, the effective communication of pertinent information to patients, and the establishment of a therapeutic partnership with the patient. It is therefore essential to carry out the deprescribing process in a collaborative and interprofessional manner, encompassing both pharmaceutical and non-pharmaceutical strategies.

背景:长期使用阿片类药物并不能明显改善临床症状,而且对慢性疼痛患者的不利影响大于有利影响。目的:探讨法国疼痛科医生对慢性非癌症患者阿片类药物停药过程的看法,并了解停药过程中的障碍和杠杆作用:我们采用定性方法开展了一项多中心观察研究。我们采用了半结构式访谈法,通过访谈指南探讨疼痛科医生的看法、信念和表述,以评估阿片类药物去处方化的决定因素。在核对访谈记录后,对访谈进行了归纳和独立的主题分析,以便从数据集中提取有意义的主题:结果:12 位疼痛科医生接受了访谈。去处方化的主要障碍围绕患者的特定属性、阿片类药物本身的特点以及当前医疗保健系统的局限性,这些因素阻碍了对患者的最佳管理。相反,患者的动机和教育、在疼痛科住院并接受多学科治疗、全科医生的随访以及在患者和临床医生中开展培训和信息传播则是促进阿片类药物停药的因素:本研究强调,需要加强对医护人员的培训,向患者有效传达相关信息,并与患者建立治疗伙伴关系。因此,必须以协作和跨专业的方式执行停药程序,其中包括药物和非药物策略。
{"title":"Determinants of successful opioid deprescribing: Insights from French pain physicians-A qualitative study.","authors":"Pierre Nizet, Laure Deme, Adrien Evin, Emmanuelle Kuhn, Julien Nizard, Caroline Victorri Vigneau, Jean-François Huon","doi":"10.1111/papr.13409","DOIUrl":"https://doi.org/10.1111/papr.13409","url":null,"abstract":"<p><strong>Background: </strong>Long-term use of opioids does not result in significant clinical improvement and has shown more adverse than beneficial effects in chronic pain conditions. When opioids cause more adverse effects than benefits for the patient, it may be necessary to initiate a process of deprescribing.</p><p><strong>Aim: </strong>To explore the perceptions of French pain physicians regarding the process of opioid deprescribing in patients experiencing chronic non-cancer and to generate an understanding of the barriers and levers to the deprescribing process.</p><p><strong>Methods: </strong>We conducted a multicentric observational study with qualitative approach. Individual semi-structured interviews exploring pain physicians' perceptions, beliefs, and representations to assess the determinants of opioid deprescribing with an interview guide were used. After checking the transcripts, an inductive and independent thematic analysis of the interviews was to extract meaningful themes from the dataset.</p><p><strong>Results: </strong>Twelve pain physicians were interviewed. The main obstacles to deprescribing revolved around patient-specific attributes, characteristics of the opioids themselves, and limitations within the current healthcare system, that hinder optimal patient management. Conversely, patient motivation and education, recourse to hospitalization in a Pain Department with multidisciplinary care, follow-up by the general practitioner, and training and information dissemination among patients and clinicians emerged as facilitative elements for opioid deprescribing.</p><p><strong>Conclusion: </strong>This study underscores the needs to improve the training of healthcare professionals, the effective communication of pertinent information to patients, and the establishment of a therapeutic partnership with the patient. It is therefore essential to carry out the deprescribing process in a collaborative and interprofessional manner, encompassing both pharmaceutical and non-pharmaceutical strategies.</p>","PeriodicalId":19974,"journal":{"name":"Pain Practice","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142081194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evidence for central sensitization as classified by the central sensitization inventory in patients with pain and hypermobility. 疼痛和活动过度患者中枢敏感性清单分类的证据。
IF 2.5 3区 医学 Q2 ANESTHESIOLOGY Pub Date : 2024-08-27 DOI: 10.1111/papr.13411
Mehul J Desai, Mason Brestle, Holly Jonely

Introduction: Pain is a very common complaint among patients with hypermobile Ehlers-Danlos Syndrome (hEDS) and Hypermobility Spectrum Disorders (HSDs). Often challenging to treat, insights into the underpinnings of pain in this population have been fleeting. Central sensitization (CS) has been postulated as a potential etiological factor.

Methods: In this retrospective study, 82 consecutive patients with hEDS/HSDs were reviewed. Demographic information and Central Sensitization Inventory (CSI) results were collected.

Results: 71 of 82 (86.5%) patients demonstrated CS. Scores ranged from 12 to 94 with a median of 56. Pain scores as measured on the numerical rating scale (NRS) ranged from 2 to 10 with a mean and median of 6.

Conclusion: A large percentage of patients with pain and a diagnosis of hEDS/HSDs demonstrated evidence of central sensitization as measured using the CSI. The CSI is simple to administer. The CSI may provide clinical insights that are key to successfully managing patients with hEDS/HSDs. Further research is needed to explore the ability to classify pain phenotypes in this patient population and the impact on precision medicine.

导言:疼痛是活动过度埃勒斯-丹洛斯综合征(hEDS)和活动过度频谱障碍(HSDs)患者的常见主诉。这类患者的疼痛往往难以治疗,对其疼痛根源的研究也是昙花一现。中枢敏化(CS)被认为是一个潜在的致病因素:在这项回顾性研究中,我们回顾了 82 名连续的 hEDS/HSD 患者。结果:82 名患者中有 71 人(86.5%)患有中枢性过敏反应:结果:82 位患者中有 71 位(86.5%)表现为 CS。评分范围为 12 到 94 分,中位数为 56 分。数字评分量表(NRS)显示的疼痛评分从 2 到 10 不等,平均值和中位数均为 6.Conclusion:结论:使用 CSI 测量,很大一部分被诊断为 hEDS/HSDs 的疼痛患者都有中枢敏化的证据。CSI 操作简单。CSI 可提供临床见解,是成功管理 hEDS/HSDs 患者的关键。还需要进一步的研究来探索对这类患者的疼痛表型进行分类的能力以及对精准医疗的影响。
{"title":"Evidence for central sensitization as classified by the central sensitization inventory in patients with pain and hypermobility.","authors":"Mehul J Desai, Mason Brestle, Holly Jonely","doi":"10.1111/papr.13411","DOIUrl":"https://doi.org/10.1111/papr.13411","url":null,"abstract":"<p><strong>Introduction: </strong>Pain is a very common complaint among patients with hypermobile Ehlers-Danlos Syndrome (hEDS) and Hypermobility Spectrum Disorders (HSDs). Often challenging to treat, insights into the underpinnings of pain in this population have been fleeting. Central sensitization (CS) has been postulated as a potential etiological factor.</p><p><strong>Methods: </strong>In this retrospective study, 82 consecutive patients with hEDS/HSDs were reviewed. Demographic information and Central Sensitization Inventory (CSI) results were collected.</p><p><strong>Results: </strong>71 of 82 (86.5%) patients demonstrated CS. Scores ranged from 12 to 94 with a median of 56. Pain scores as measured on the numerical rating scale (NRS) ranged from 2 to 10 with a mean and median of 6.</p><p><strong>Conclusion: </strong>A large percentage of patients with pain and a diagnosis of hEDS/HSDs demonstrated evidence of central sensitization as measured using the CSI. The CSI is simple to administer. The CSI may provide clinical insights that are key to successfully managing patients with hEDS/HSDs. Further research is needed to explore the ability to classify pain phenotypes in this patient population and the impact on precision medicine.</p>","PeriodicalId":19974,"journal":{"name":"Pain Practice","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142081195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Pain Practice
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1